Fierce Pharma
ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data
Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...
Pfizer Inc. (PFE) announces results from the phase 3 BASIS study evaluating HYMPAVZI
Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results ...
NBC News
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The agency ...
Pfizer's Hemophilia Drug Data Signals Strategic Shift
The Phase 3 "BASIS" trial data, showcased at the American Society of Hematology (ASH) annual meeting, showed significant promise. For patients with inhibitors—a subgroup historically difficult to ...